Chronic Insomnia Market

• The Chronic Insomnia market is projected to witness sustained growth from 2025 to 2034, fueled by increased awareness of sleep disorders, growing diagnosis rates, and an aging population with increased vulnerability to sleep disturbances. Advancements in pharmacological therapies, alongside ongoing clinical development efforts, are expected to drive therapeutic innovation and broaden treatment options, supporting long-term market expansion.
• QUVIVIQ (daridorexant) by Idorsia and DAYVIGO (lemborexant) by Eisai are dual orexin receptor antagonists (DORAs) approved for treating chronic insomnia. They block orexin receptors OX1R and OX2R to suppress wakefulness and promote natural sleep. These therapies represent a shift toward targeted, neurobiology-based treatments that improve sleep onset and maintenance with minimal next-day impairment.
• The pipeline for chronic insomnia remains limited, reflecting a stagnation in innovation. While recent approvals have improved treatment options, the absence of diverse, late-stage candidates highlights an urgent need for research into new mechanisms and personalized approaches.
• Market growth in chronic insomnia is supported by the development of advanced therapeutics and improved formulations that better address the long-term nature of the disorder. While conventional treatments such as sedative-hypnotics and over-the-counter sleep aids remain common, concerns about side effects, tolerance, and limited long-term effectiveness highlight the need for more reliable options. New therapies are focused on improving sleep quality, minimizing adverse effects, and offering sustained relief, ultimately aiming to enhance patient outcomes and quality of life.

Factors affecting Chronic Insomnia Market Growth

• Rising Prevalence of Sleep Disorders
  Increasing cases of chronic insomnia due to stress, lifestyle changes, and medical comorbidities are driving demand for effective treatment options.

• Advancements in Diagnostic Tools
  Improved sleep monitoring technologies, polysomnography, and wearable devices enable accurate diagnosis and personalized treatment.

• Development of Novel Therapies
  Introduction of new pharmacological treatments, cognitive behavioral therapy for insomnia (CBT-I), and digital therapeutics is enhancing patient outcomes.

• Growing Awareness Among Healthcare Professionals
  Increased recognition of the impact of insomnia on overall health is contributing to better diagnosis and adoption of effective treatment regimens.

• Rising Patient Awareness and Health Consciousness
  Patients are increasingly seeking solutions for sleep disturbances, driving demand for therapies and monitoring solutions.

• Expansion of Healthcare Infrastructure
  Availability of sleep clinics, mental health facilities, and telemedicine services improves access to diagnosis and treatment.

• Lifestyle and Work Pressure Trends
  High-stress lifestyles, longer working hours, and increased screen time are contributing to insomnia prevalence, further driving market growth.

DelveInsight’s comprehensive report titled “Chronic Insomnia — Market Insights, Epidemiology, and Market Forecast – 2034” offers a detailed analysis of chronic Insomnia. The report presents historical and projected epidemiological data covering prevalent cases of chronic Insomnia, diagnosed prevalent cases of chronic Insomnia, gender-specific cases of chronic Insomnia, age-specific cases of chronic Insomnia, and treated cases of chronic Insomnia. In addition to epidemiology, the market report encompasses various aspects related to the patient population. These aspects include the diagnosis process, prescription patterns, physician perspectives, market accessibility, treatment options, and prospective developments in the market across seven major markets: the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan, spanning from 2020 to 2034.

The report analyzes the existing treatment practices and unmet medical requirements in chronic Insomnia. It evaluates the market potential and identifies potential business prospects for enhancing therapies or interventions. This valuable information enables stakeholders to make well-informed decisions regarding product development and strategic planning for the market.

Chronic Insomnia Overview

Chronic insomnia is the most common sleep disorder and often surfaces as a key issue in primary care settings. As defined by the International Classification of Sleep Disorders, Third Edition (ICSD-3) from the American Academy of Sleep Medicine, it involves persistent problems with falling asleep, staying asleep, or achieving restorative sleep. These disturbances must occur at least three times per week and persist for over three months, despite sufficient chances to sleep. Diagnosis relies mainly on the patient's self-reported sleep difficulties and related daytime impairment.

Chronic insomnia negatively impacts overall health, quality of life, and academic achievement. It also heightens the risk of motor vehicle accidents, reduces workplace productivity, contributes to irritability, and leads to excessive daytime sleepiness. The condition is frequently linked with a range of comorbidities, such as depression, anxiety, posttraumatic stress disorder, hypertension, chronic pain, gastroesophageal reflux disease, chronic obstructive pulmonary disease, asthma, benign prostatic hyperplasia, obstructive sleep apnea, vasomotor symptoms, and substance use disorders.

Chronic Insomnia Diagnosis and Treatment Algorithm 

Chronic insomnia is primarily diagnosed through a detailed assessment of the individual's sleep, medical, psychiatric, and substance use history. Routine lab or imaging studies are not typically required but may be ordered if underlying medical conditions are suspected, such as thyroid dysfunction, anemia, or neurological issues. Recommended tests may include blood panels, ECG, EEG, or circadian markers like melatonin. Sleep diaries, maintained for 7–14 days, are useful, low-cost tools to evaluate sleep patterns, caffeine/alcohol use, and nap habits, though reliability may vary.

Validated tools such as the Insomnia Severity Index (ISI), Sleep Condition Indicator, Epworth Sleepiness Scale, and Pittsburgh Sleep Quality Index help assess the severity and impact of insomnia. Polysomnography is reserved for suspected sleep-related breathing or movement disorders, not routine primary insomnia. Actigraphy, a wearable device tracking motor activity, helps monitor sleep parameters in suspected circadian rhythm disorders, though it cannot detect limb movements or breathing abnormalities.

CBT-I is the first-line treatment for chronic insomnia, supported by international guidelines for its effectiveness in improving sleep and associated daytime symptoms. It includes behavioral strategies like sleep restriction, stimulus control, and sleep hygiene, along with relaxation techniques such as deep breathing and meditation. CBT-I is based on the three-factor model of insomnia and is typically delivered by trained therapists, either individually or in groups.

When CBT-I is insufficient, pharmacological options may be considered. These include GABA-A receptor agonists (e.g., zolpidem, eszopiclone), orexin receptor antagonists (e.g., suvorexant), melatonin receptor agonists (e.g., ramelteon), low-dose antidepressants (e.g., doxepin), and anticonvulsants (e.g., gabapentin). Each drug class has specific benefits and risks, including sedation, dependence, or cognitive impairment. Guidelines recommend short-term use with caution in older adults. Sedating antihistamines and herbal remedies lack strong evidence and are generally not advised. 

Chronic Insomnia Epidemiology

The epidemiology section of the chronic Insomnia market report offers information on the patient populations, including historical and projected trends for each of the seven major markets. Examining key opinion leader views from physicians or clinical experts can assist in identifying the reasons behind historical and projected trends. The diagnosed patient pool, their trends, and the underlying assumptions are all included in this section of the report.

This section also presents the data with relevant tables and graphs, offering a clear and concise view of the prevalence of chronic Insomnia. Additionally, the report discloses the assumptions made during the analysis, ensuring data interpretation and presentation transparency. This epidemiological data is valuable for understanding the disease burden and its impact on the patient population across various regions.

Key Findings

According to American Academy of Sleep Medicine, 12% of Americans have been diagnosed with chronic insomnia, based on recent survey findings.

According to the International Classification of Sleep Disorders, 3rd edition (ICSD-3), the prevalence of chronic insomnia disorder in the Spanish general adult population is ~14%.

As per secondary research, Insomnia tends to be more prevalent in middle-aged and older adults, women, and individuals with underlying medical or psychiatric conditions. 

The epidemiology of chronic Insomnia is expected to change during the forecast period (2025-2034).

Chronic Insomnia Market Outlook

The chronic Insomnia therapeutics market is further expected to increase by the major drivers, such as the rising prevalence population, technological advancements, and upcoming therapies in the forecast period (2025–2034).

With ongoing research and continued dedication, the future holds hope for even more effective treatments and, ultimately, a cure for this challenging condition. According to DelveInsight, the chronic Insomnia market in the 7MM is expected to change significantly during the forecast period 2025–2034.

Chronic Insomnia Drug Chapters 

Marketed Chronic Insomnia Drugs

QUVIVIQ (daridorexant): IDORSIA

QUVIVIQ is a dual orexin receptor antagonist (DORA), which blocks the binding of the wake-promoting neuropeptides orexins. DORAs are thought to turn down overactive wakefulness, as opposed to sedating the brain. QUVIVIQ is a prescription medication indicated for the treatment of adult patients with insomnia. It is a tablet taken orally once per night within 30 minutes before going to bed with at least seven hours remaining before planned awakening.

In January 2022, Idorsia announced that the US FDA has approved QUVIVIQ (daridorexant) 25 mg and 50 mg for the treatment of adult patients with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance.

DAYVIGO (lemborexant): EISAI

DAYVIGO (Lemborexant), developed by Eisai, is a small-molecule competitive antagonist of orexin receptors (OX1R and OX2R). It is believed to treat insomnia by blocking orexin A and B, thereby reducing wakefulness and promoting sleep.

In December 2019, Eisai announced that the US FDA has approved the new drug application for DAYVIGO (lemborexant), an orexin receptor antagonist developed in-house by the company.

In January 2020, Eisai announced that it has received manufacturing and marketing approval in Japan for DAYVIGO (lemborexant), its internally developed orexin receptor antagonist, for the treatment of insomnia.

Note: Detailed marketed therapies assessment will be provided in the final report

Chronic Insomnia Market Segmentation

DelveInsight’s ‘Chronic Insomnia– Market Insights, Epidemiology, and Market Forecast – 2034’ report provides a detailed outlook of the current and future chronic Insomnia market, segmented within countries, by therapies, and by classes. Further, the market of each region is then segmented by each therapy to provide a detailed view of the current and future market share of all therapies. 

Chronic Insomnia Market Size by Countries

The chronic Insomnia market size is assessed separately for various countries, including the United States, EU4 (Germany, France, Italy, and Spain), the UK, and Japan. In 2024, the United States held a significant share of the overall 7MM (Seven Major Markets) chronic Insomnia market, primarily attributed to the country’s higher prevalence of the condition and the elevated cost of the available treatments. This dominance is projected to persist, especially with the potential early introduction of new products.

Chronic Insomnia Market Size by Therapies

Chronic Insomnia Market Size by Therapies is categorized into current and emerging markets for the study period 2020–2034. 

Note: Detailed market segment assessment will be provided in the final report.

Chronic Insomnia Drugs Uptake

This section focuses on the sales uptake of potential chronic Insomnia drugs that have recently been launched or are anticipated to be launched in the chronic Insomnia market between 2020 and 2034. It estimates the market penetration of chronic Insomnia drugs for a given country, examining their impact within and across classes and segments. It also touches upon the financial and regulatory decisions contributing to the probability of success (PoS) of the drugs in the chronic Insomnia market.

The emerging chronic Insomnia therapies are analyzed based on various attributes such as safety and efficacy in randomized clinical trials, order of entry and other market dynamics, and the unmet need they fulfill in the chronic Insomnia market.

Note: Detailed assessment of drug uptake and attribute analysis will be provided in the full report on chronic Insomnia.

Chronic Insomnia Market Access and Reimbursement

DelveInsight’s ‘Chronic Insomnia– Market Insights, Epidemiology, and Market Forecast – 2034’ report provides a descriptive overview of the market access and reimbursement scenario of chronic Insomnia.

This section includes a detailed analysis of the country-wise healthcare system for each therapy, enlightening the market access, reimbursement policies, and health technology assessments. 

KOL Views

To keep up with current chronic Insomnia market trends and fill gaps in secondary findings, we interview KOLs and SMEs’ working in the chronic Insomnia domain. Their opinion helps understand and validate current and emerging therapies and treatment patterns or chronic Insomnia market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the chronic Insomnia unmet needs.

Chronic Insomnia: KOL Insights

DelveInsight’s analysts connected with 50+ KOLs to gather insights; however, interviews were conducted with 15+ KOLs in the 7MM. These KOLs were from organizations, institutes, and hospitals, such as University of Missouri, US, Universitätsmedizin, Germany, Hospital Universitari Vall d'Hebrón, Spain, Université Paris Cité, France, University of Southampton, UK, and Kyorin University, Japan, among others.

“Chronic insomnia may be primary or secondary, but its impact is similar, making it a distinct clinical disorder. While factors like hyperarousal, stress reactivity, psychological, and circadian influences are known contributors, how they interact to cause chronic insomnia is still not fully understood.”

“Cognitive behavioural therapy for insomnia (CBT-I) is endorsed as the first-line treatment for chronic insomnia, or cases at risk of becoming chronic, by organizations like the National Institute for Health and Care Excellence and the American College of Physicians. Unlike basic sleep hygiene, CBT-I targets the underlying thoughts and behaviors that contribute to sleep problems.”

“Insomnia imposes a significant humanistic and economic burden, affecting both quality of life and healthcare systems globally. This includes direct costs such as expenses for medications and therapy, as well as indirect costs like lost productivity, sick leave, early retirement, and reduced social functioning.”

Note: Detailed assessment of KOL Views will be provided in the full report chronic Insomnia.

Competitive Intelligence Analysis

We conduct a Competitive and Market Intelligence analysis of the chronic Insomnia Market, utilizing various Competitive Intelligence tools such as SWOT analysis and Market entry strategies. The inclusion of these analyses is contingent upon data availability, ensuring a comprehensive and well-informed assessment of the market landscape and competitive dynamics.

Chronic Insomnia Pipeline Development Activities

The report offers an analysis of therapeutic candidates in Phase II and III stages and examines companies involved in developing targeted therapeutics for chronic insomnia. It provides valuable insights into the advancements and progress of potential treatments in clinical development for this condition.

Pipeline Development Activities

The report covers information on collaborations, acquisition and merger, licensing, patent details, and other information for emerging chronic insomnia therapies.

Chronic Insomnia Report Insights

• Chronic Insomnia Patient Population
• Therapeutic Approaches
• Chronic Insomnia Pipeline Analysis
• Chronic Insomnia Market Size and Trends
• Chronic Insomnia Market Opportunities
• Impact of Upcoming Therapies

Chronic Insomnia Report Key Strengths

• 10 Years Forecast
• The 7MM Coverage
• Chronic Insomnia Epidemiology Segmentation
• Key Cross Competition
• Highly Analyzed Chronic Insomnia Market
• Chronic Insomnia Drugs Uptake

Chronic Insomnia Report Assessment

• Chronic Insomnia Current Treatment Practices
• Unmet Needs
• Chronic Insomnia Pipeline Product Profiles
• Chronic Insomnia Market Attractiveness

Key Questions

• How common is chronic Insomnia?
• What are the key findings of chronic Insomnia epidemiology across the 7MM, and which country will have the highest number of patients during the study period (2020–2034)?
• What are the currently available treatments for chronic Insomnia?
• What are the disease risk, burden, and unmet needs of chronic Insomnia?
• At what CAGR is the chronic Insomnia market and its epidemiology is expected to grow in the 7MM during the forecast period (2025–2034)?
• How would the unmet needs impact the chronic Insomnia market dynamics and subsequently influence the analysis of the related trends?
• What would be the forecasted patient pool of chronic Insomnia in the 7MM covering the United States, EU4 (Germany, France, Italy, and Spain), the UK, and Japan?
• Among EU4 and the UK, which country will have the highest number of patients during the forecast period (2025–2034)?
• How many companies are currently developing therapies for the treatment of chronic Insomnia?   

Reasons to buy

• The report will help in developing business strategies by understanding the latest trends and changing treatment dynamics driving the chronic Insomnia Market.
• Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• To understand the existing market opportunity in varying geographies and the growth potential over the coming years.
• Distribution of historical and current patient share based on real-world prescription data along with reported sales of current treatment in the US, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
• Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
• Detailed analysis and ranking of class-wise potential current and emerging therapies under the conjoint analysis section to provide visibility around leading classes.
• Highlights of Access and Reimbursement policies of approved therapies, barriers to accessibility of off-label expensive therapies, and patient assistance programs.
• To understand the perspective of Key Opinion Leaders around the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future. 
• Detailed insights on the unmet needs of the existing market so that the upcoming players can strengthen their development and launch strategy.